1[1]World Health Organization.Assessment of fracture risksand its application to screening for postmenopausal osteoporosis.WHO Technical Report Series 843.Geneva:WHO.1994.
2[2]Slemenda CW,Christian JC,Williams CJ,et al.Genetic determinants of bone mass in adult women:a reevaluation of the twin model and thepotential importance of gene interaction on heritability estimates.J Bone Miner Res,1991,6:561-567.
3[3]Taaffe DR,Robinson TL,Snow CM,et al.Highimpactexercise promotes bone gain in well-trained female athletes.J Bone Miner Res,1997,12:255-260.
4[4]Rapuri PB,Gallagher JC,Balhorn KE,et al.Alcohol intake and bone metabolism in elderly women.Am J Clin Nutr,2000,72:1206-1213.
5[5]ACOG Practice Bulletin No.50.Osteoporosis.Clinical management guidelines for ogstetrician-gynecologists.Obstetrics and Gynecsology,2004,103:203-216.
6[6]Kanis JA,Johnell O,Oden A,et al.Risk of hip fracture derived from relative risks:an analysis applied to the population of Sweden.Osteoporos Int,2000,11:120-127.
7[7]Rossouw JE,Anderson GL,Prentice RL,et al.Risks and benefits of estrogen plus progestin in healthy postmenopausal women:principal results from the Women' s Health Initiative randomized controlled trial.JAMA,2002,288:321-333.
8[8]Lindsay R,Gallagher JC,Kleerekoper M,et al.Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early post-menopausal women.JAMA,2002,287:2668-2676.
9[10]Gallagher JC,Baylink DJ,Freeman R,et al.Prevention of bone loss with tibolone in postmenopausal women:results of two randomized,double-blind,placebo-controlled,dose-finding studies.J Clin Endocrinol Metab,2001,86:4717-4726.
10[11]Black DM,Thompson DE,Bauer DC,et al.Fracture risk reduction with alendronate in women with osteoporosis:the Fracture Intervention Trial.FIT Research Group.J Clin Endocrinol Metab,2000,85:4118-4124.
